+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma

Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma

Statistical Methods in Medical Research 27(5): 1451-1463

Trials run in either rare diseases, such as rare cancers, or rare sub-populations of common diseases are challenging in terms of identifying, recruiting and treating sufficient patients in a sensible period. Treatments for rare diseases are often designed for other disease areas and then later proposed as possible treatments for the rare disease after initial phase I testing is complete. To ensure the trial is in the best interests of the patient participants, frequent interim analyses are needed to force the trial to stop promptly if the treatment is futile or toxic. These non-definitive phase II trials should also be stopped for efficacy to accelerate research progress if the treatment proves to be particularly promising. In this paper, we review frequentist and Bayesian methods that have been adapted to incorporate two binary endpoints and frequent interim analyses. The Eurosarc Trial of Linsitinib in advanced Ewing Sarcoma (LINES) is used as a motivating example and provides a suitable platform to compare these approaches. The Bayesian approach provides greater design flexibility, but does not provide additional value over the frequentist approaches in a single trial setting when the prior is non-informative. However, Bayesian designs are able to borrow from any previous experience, using prior information to improve efficiency.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057192537

Download citation: RISBibTeXText

PMID: 27587590

DOI: 10.1177/0962280216662070

Related references

Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. Clinical Sarcoma Research 2(1): 5-5, 2012

Optimal planning of phase II/III programs for clinical trials with multiple endpoints. Pharmaceutical Statistics: -, 2018

Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survival. Critical Reviews in Oncology/Hematology 88(2): 309-317, 2014

The analysis of multiple endpoints in clinical trials. Biometrics 43(3): 487-498, 1987

What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials. Bulletin du Cancer 101(4): E19-E24, 2014

Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints. Journal of Biopharmaceutical Statistics: 1-16, 2017

Letter to the editor Secondary cancers after Ewing sarcoma and Ewing sarcoma as second malignant neoplasm. Medical & Pediatric Oncology 30(4): 259-260, April, 1998

On the design and analysis of randomized clinical trials with multiple endpoints. Biometrics. 49(1): 23-30, 1993

Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints. Biometrics: -, 2018

Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. Therapeutic Innovation & Regulatory Science: 2168479017728989-2168479017728989, 2018

Resampling-based methods for the analysis of multiple endpoints in clinical trials. Statistics in Medicine 18(24): 3453-3462, Dec 30, 1999

Design and analysis of group sequential clinical trials with multiple primary endpoints. Biometrics 60(1): 134-145, 2004

"Secondary cancers after Ewing sarcoma and Ewing sarcoma as second malignant neoplasm". Medical and Pediatric Oncology 30(4): 259-260, 1998

Ewing's Sarcoma of the Stomach; Rare Case of Ewing's Sarcoma and Suggestion of New Treatment Strategy. Journal of Gastric Cancer 12(4): 258-261, 2013

Multiple comparisons in non-inferiority trials: Reaction to recent regulatory guidance on multiple endpoints in clinical trials. Journal of Biopharmaceutical Statistics 28(1): 52-62, 2017